ClinicalTrials.gg
Not yet recruitingNCT07119905Updated Aug 13, 2025

Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital

An observational study in Primary Open Angle Glaucoma (POAG), sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Sohag University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Glaucoma, Open-Angle with a site in Egypt — 5 open to participants now, 6 under way, none of them phase 3. Glaucoma, Open-Angle · Egypt.

Started
2026
with 2 others
Observational
8 of 25
2 open now
Registered
18th of 25
by date
Lead sponsor
2 of 25
Sohag University

Among the 25 studies in Glaucoma, Open-Angle with a site in Egypt, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 18th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

5 of the 25 studies in Glaucoma, Open-Angle with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 30 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Glaucoma, Open-Angle with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to

Read the detailed description

Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual field, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place

POAG is the most common type of glaucoma that is characterized by specific glaucomatous retinal, optic nerve, and clinical findings without a clear secondary cause.

POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual field in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP).

Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.

The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outflow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor.

Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.

03

Conditions studied

  • Primary Open Angle Glaucoma (POAG)

Browse trials for

Keywords

  • Primary Open Angle Glaucoma
  • POAG
  • Gene Polymorphism
  • MMP-9
  • Matrix Metalloproteinase-9 Gene Polymorphism
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with Primary Open Angle Glaucoma in Department of ophthalmology in Sohag University Hospitals and healthy controls of matched age and sex

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women older than 30 years
  • Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
  • Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion criteria

Exclusion Criteria:

  • Exfoliation glaucoma, pigmentary glaucoma
  • History of acute angle closure
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group

    Normal healthy volunteers aged \> 30 years

    Genetic: genotyping assay by polymerase chain reaction

  • Experimental Group

    Patients aged \>30 years and diagnosed with Primary Open Angle Glaucoma

    Genetic: genotyping assay by polymerase chain reaction

Interventions

  • Geneticgenotyping assay by polymerase chain reaction

    Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube. Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

06

What researchers measure

Primary outcomes

  1. Matrix metalloproteinase-9 gene polymorphism

    Matrix metalloproteinase-9 gene polymorphism by polymerase chain reaction

    Time frame: 14 months

07

Study locations

1 site
  • Sohag University Hosipital
    Sohag, Sohag Governorate 82525, Egypt
08

References and documents

Publications

  • Grzybowski A, Och M, Kanclerz P, Leffler C, Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med. 2020 Mar 11;9(3):761. doi: 10.3390/jcm9030761. PubMed 32168880 ↗
  • Liu Y, Allingham RR. Major review: Molecular genetics of primary open-angle glaucoma. Exp Eye Res. 2017 Jul;160:62-84. doi: 10.1016/j.exer.2017.05.002. Epub 2017 May 10. PubMed 28499933 ↗
  • Zhao F, Fan Z, Huang X. Role of matrix metalloproteinase-9 gene polymorphisms in glaucoma: A hospital-based study in Chinese patients. J Clin Lab Anal. 2020 Mar;34(3):e23105. doi: 10.1002/jcla.23105. Epub 2019 Nov 12. PubMed 31713905 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2025
First posted
Aug 13, 2025
StartEst.
Jun 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119905
Lead sponsor
Sohag University
Responsible party
Thomas Talaat Nageh (Demonstrator, Sohag University) — Principal investigator
First posted
Aug 13, 2025
Start date
Jun 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Aug 13, 2025

Study contacts

Thomas Talaat Nageh, Demonstrator
Contact
thomas.talaat@med.sohag.edu.eg
20 1276890796

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion